TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT02118584

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.
“The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

201420152016201720182019202020212022202320242025Registered2014-04-16Started2014-09-15Stopped2023-10-05Results posted2024-10-23

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
Hoffmann-La Roche
Sponsor type
Industry
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Participants
1,822
Sites
411
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.